A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Completed

Conditions studied: Advanced Cutaneous Melanoma

In brief

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting

Key facts

Study ID

NCT01511913

Run by

Bristol-Myers Squibb

People needed

1411

Starts

2012-06-03

Expected to finish

2019-12-12

Last updated by the study team

2021-12-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of unresectable or metastatic melanoma
• Age of 18 years or older at time of entry into the study
• Patients who have initiated treatment for unresectable or metastatic melanoma at medical practice (e.g. community-based, office-based, hospital-based, academic setting)within 21 days before informed consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before informed consent for this study, and treatment must be initiated within 28 days after informed consent
• Ipilimumab-treated patients must be receiving treatment for the indication(s) approved in their country of residence or where they are receiving treatment

You may not qualify if…

• Current or pending participation in a clinical trial examining therapy for the treatment of any cancer (including unresectable or metastatic melanoma)
• Current use of therapy to treat a primary cancer other than melanoma

Where it is running

• Local Institution — Hot Springs, Arkansas, United States
• Local Institution — Encinitas, California, United States
• Local Institution — La Jolla, California, United States
• Local Institution — Long Beach, California, United States
• Local Institution — Los Angeles, California, United States
• Local Institution — Denver, Colorado, United States
• Local Institution — Washington D.C., District of Columbia, United States
• Local Institution — Lakeland, Florida, United States
• Local Institution — Miami Beach, Florida, United States
• Local Institution — Orange Park, Florida, United States
• Local Institution — Chicago, Illinois, United States
• Local Institution — Niles, Illinois, United States
• Local Institution — Detroit, Michigan, United States
• Local Institution — Hattiesburg, Mississippi, United States
• Local Institution — Lincoln, Nebraska, United States
• Local Institution — Morristown, New Jersey, United States
• Local Institution — Canton, Ohio, United States
• Mid Ohio Onc/Hem, Inc — Columbus, Ohio, United States
• Local Institution — Columbus, Ohio, United States
• Local Institution — Middletown, Ohio, United States
• Local Institution — Portland, Oregon, United States
• Local Institution — Knoxville, Tennessee, United States
• Local Institution — Everett, Washington, United States
• Local Institution — CABA, Argentina
• Local Institution — Gilbert, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.